nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—XDH—Doxorubicin—pancreatic cancer	0.303	0.348	CbGbCtD
Pyrazinamide—CYP1A2—Dacarbazine—pancreatic cancer	0.118	0.136	CbGbCtD
Pyrazinamide—CYP1A2—Tamoxifen—pancreatic cancer	0.0942	0.108	CbGbCtD
Pyrazinamide—CYP1A2—Erlotinib—pancreatic cancer	0.0801	0.092	CbGbCtD
Pyrazinamide—CYP1A2—Fluorouracil—pancreatic cancer	0.0694	0.0797	CbGbCtD
Pyrazinamide—CYP3A4—Tamoxifen—pancreatic cancer	0.0494	0.0567	CbGbCtD
Pyrazinamide—CYP3A4—Erlotinib—pancreatic cancer	0.042	0.0482	CbGbCtD
Pyrazinamide—CYP3A4—Irinotecan—pancreatic cancer	0.0379	0.0435	CbGbCtD
Pyrazinamide—CYP3A4—Docetaxel—pancreatic cancer	0.0278	0.0319	CbGbCtD
Pyrazinamide—CYP3A4—Sunitinib—pancreatic cancer	0.0277	0.0318	CbGbCtD
Pyrazinamide—CYP3A4—Doxorubicin—pancreatic cancer	0.0207	0.0238	CbGbCtD
Pyrazinamide—Peptic ulcer—Erlotinib—pancreatic cancer	0.00409	0.0317	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Tamoxifen—pancreatic cancer	0.00358	0.0277	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Erlotinib—pancreatic cancer	0.00354	0.0274	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Sunitinib—pancreatic cancer	0.00306	0.0237	CcSEcCtD
Pyrazinamide—Hepatomegaly—Irinotecan—pancreatic cancer	0.00275	0.0213	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Sunitinib—pancreatic cancer	0.00255	0.0198	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Gemcitabine—pancreatic cancer	0.00246	0.019	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Sunitinib—pancreatic cancer	0.00241	0.0187	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Sunitinib—pancreatic cancer	0.00215	0.0167	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Docetaxel—pancreatic cancer	0.00174	0.0135	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Fluorouracil—pancreatic cancer	0.0017	0.0131	CcSEcCtD
Pyrazinamide—Photosensitivity—Fluorouracil—pancreatic cancer	0.00154	0.012	CcSEcCtD
Pyrazinamide—Hepatitis—Tamoxifen—pancreatic cancer	0.00139	0.0107	CcSEcCtD
Pyrazinamide—Hepatitis—Erlotinib—pancreatic cancer	0.00137	0.0106	CcSEcCtD
Pyrazinamide—Hepatomegaly—Epirubicin—pancreatic cancer	0.00128	0.00995	CcSEcCtD
Pyrazinamide—Hepatitis—Sunitinib—pancreatic cancer	0.00119	0.0092	CcSEcCtD
Pyrazinamide—Hepatomegaly—Doxorubicin—pancreatic cancer	0.00119	0.0092	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Fluorouracil—pancreatic cancer	0.00107	0.00828	CcSEcCtD
Pyrazinamide—Myalgia—Tamoxifen—pancreatic cancer	0.00103	0.00796	CcSEcCtD
Pyrazinamide—Arthralgia—Tamoxifen—pancreatic cancer	0.00103	0.00796	CcSEcCtD
Pyrazinamide—Myalgia—Erlotinib—pancreatic cancer	0.00102	0.00788	CcSEcCtD
Pyrazinamide—Arthralgia—Erlotinib—pancreatic cancer	0.00102	0.00788	CcSEcCtD
Pyrazinamide—Discomfort—Tamoxifen—pancreatic cancer	0.00102	0.00787	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Epirubicin—pancreatic cancer	0.000979	0.00759	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.000964	0.00748	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Erlotinib—pancreatic cancer	0.000954	0.0074	CcSEcCtD
Pyrazinamide—Anorexia—Tamoxifen—pancreatic cancer	0.000939	0.00728	CcSEcCtD
Pyrazinamide—Anorexia—Erlotinib—pancreatic cancer	0.000929	0.0072	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Epirubicin—pancreatic cancer	0.000925	0.00717	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Doxorubicin—pancreatic cancer	0.000906	0.00702	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.000897	0.00696	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.000888	0.00688	CcSEcCtD
Pyrazinamide—Myalgia—Sunitinib—pancreatic cancer	0.00088	0.00682	CcSEcCtD
Pyrazinamide—Arthralgia—Sunitinib—pancreatic cancer	0.00088	0.00682	CcSEcCtD
Pyrazinamide—Dyspepsia—Tamoxifen—pancreatic cancer	0.000867	0.00672	CcSEcCtD
Pyrazinamide—Dyspepsia—Erlotinib—pancreatic cancer	0.000858	0.00665	CcSEcCtD
Pyrazinamide—Decreased appetite—Tamoxifen—pancreatic cancer	0.000856	0.00664	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Doxorubicin—pancreatic cancer	0.000856	0.00663	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00085	0.00659	CcSEcCtD
Pyrazinamide—Decreased appetite—Erlotinib—pancreatic cancer	0.000847	0.00657	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000841	0.00652	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000826	0.0064	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Epirubicin—pancreatic cancer	0.000825	0.0064	CcSEcCtD
Pyrazinamide—Anorexia—Sunitinib—pancreatic cancer	0.000804	0.00623	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Irinotecan—pancreatic cancer	0.00079	0.00612	CcSEcCtD
Pyrazinamide—Urticaria—Tamoxifen—pancreatic cancer	0.000782	0.00607	CcSEcCtD
Pyrazinamide—Body temperature increased—Erlotinib—pancreatic cancer	0.00077	0.00597	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Gemcitabine—pancreatic cancer	0.00077	0.00596	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000769	0.00596	CcSEcCtD
Pyrazinamide—Malaise—Irinotecan—pancreatic cancer	0.000768	0.00595	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Doxorubicin—pancreatic cancer	0.000764	0.00592	CcSEcCtD
Pyrazinamide—Photosensitivity—Epirubicin—pancreatic cancer	0.000751	0.00582	CcSEcCtD
Pyrazinamide—Malaise—Gemcitabine—pancreatic cancer	0.000748	0.0058	CcSEcCtD
Pyrazinamide—Dyspepsia—Sunitinib—pancreatic cancer	0.000743	0.00576	CcSEcCtD
Pyrazinamide—Decreased appetite—Sunitinib—pancreatic cancer	0.000733	0.00568	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000728	0.00565	CcSEcCtD
Pyrazinamide—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000726	0.00562	CcSEcCtD
Pyrazinamide—Discomfort—Irinotecan—pancreatic cancer	0.000716	0.00555	CcSEcCtD
Pyrazinamide—Myalgia—Gemcitabine—pancreatic cancer	0.000706	0.00547	CcSEcCtD
Pyrazinamide—Arthralgia—Gemcitabine—pancreatic cancer	0.000706	0.00547	CcSEcCtD
Pyrazinamide—Discomfort—Gemcitabine—pancreatic cancer	0.000698	0.00541	CcSEcCtD
Pyrazinamide—Pruritus—Tamoxifen—pancreatic cancer	0.000697	0.0054	CcSEcCtD
Pyrazinamide—Photosensitivity—Doxorubicin—pancreatic cancer	0.000695	0.00538	CcSEcCtD
Pyrazinamide—Myalgia—Fluorouracil—pancreatic cancer	0.000694	0.00538	CcSEcCtD
Pyrazinamide—Pruritus—Erlotinib—pancreatic cancer	0.000689	0.00534	CcSEcCtD
Pyrazinamide—Discomfort—Fluorouracil—pancreatic cancer	0.000686	0.00532	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00068	0.00527	CcSEcCtD
Pyrazinamide—Hepatitis—Docetaxel—pancreatic cancer	0.000676	0.00524	CcSEcCtD
Pyrazinamide—Body temperature increased—Sunitinib—pancreatic cancer	0.000667	0.00517	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000663	0.00514	CcSEcCtD
Pyrazinamide—Anorexia—Irinotecan—pancreatic cancer	0.000662	0.00513	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000652	0.00505	CcSEcCtD
Pyrazinamide—Anorexia—Gemcitabine—pancreatic cancer	0.000645	0.005	CcSEcCtD
Pyrazinamide—Anorexia—Fluorouracil—pancreatic cancer	0.000634	0.00492	CcSEcCtD
Pyrazinamide—Vomiting—Tamoxifen—pancreatic cancer	0.000626	0.00485	CcSEcCtD
Pyrazinamide—Hypersensitivity—Sunitinib—pancreatic cancer	0.000622	0.00482	CcSEcCtD
Pyrazinamide—Rash—Tamoxifen—pancreatic cancer	0.000621	0.00481	CcSEcCtD
Pyrazinamide—Dermatitis—Tamoxifen—pancreatic cancer	0.00062	0.00481	CcSEcCtD
Pyrazinamide—Vomiting—Erlotinib—pancreatic cancer	0.00062	0.0048	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000617	0.00478	CcSEcCtD
Pyrazinamide—Rash—Erlotinib—pancreatic cancer	0.000614	0.00476	CcSEcCtD
Pyrazinamide—Dermatitis—Erlotinib—pancreatic cancer	0.000614	0.00476	CcSEcCtD
Pyrazinamide—Dyspepsia—Irinotecan—pancreatic cancer	0.000612	0.00474	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000606	0.0047	CcSEcCtD
Pyrazinamide—Decreased appetite—Irinotecan—pancreatic cancer	0.000604	0.00468	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.0006	0.00465	CcSEcCtD
Pyrazinamide—Pruritus—Sunitinib—pancreatic cancer	0.000597	0.00463	CcSEcCtD
Pyrazinamide—Decreased appetite—Gemcitabine—pancreatic cancer	0.000588	0.00456	CcSEcCtD
Pyrazinamide—Dyspepsia—Fluorouracil—pancreatic cancer	0.000586	0.00454	CcSEcCtD
Pyrazinamide—Nausea—Tamoxifen—pancreatic cancer	0.000585	0.00453	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000584	0.00453	CcSEcCtD
Pyrazinamide—Nausea—Erlotinib—pancreatic cancer	0.000579	0.00449	CcSEcCtD
Pyrazinamide—Decreased appetite—Fluorouracil—pancreatic cancer	0.000579	0.00448	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000575	0.00445	CcSEcCtD
Pyrazinamide—Feeling abnormal—Irinotecan—pancreatic cancer	0.000573	0.00444	CcSEcCtD
Pyrazinamide—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000558	0.00432	CcSEcCtD
Pyrazinamide—Body temperature increased—Irinotecan—pancreatic cancer	0.000549	0.00426	CcSEcCtD
Pyrazinamide—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000548	0.00425	CcSEcCtD
Pyrazinamide—Vomiting—Sunitinib—pancreatic cancer	0.000536	0.00416	CcSEcCtD
Pyrazinamide—Body temperature increased—Gemcitabine—pancreatic cancer	0.000535	0.00415	CcSEcCtD
Pyrazinamide—Dysuria—Epirubicin—pancreatic cancer	0.000533	0.00413	CcSEcCtD
Pyrazinamide—Rash—Sunitinib—pancreatic cancer	0.000532	0.00412	CcSEcCtD
Pyrazinamide—Dermatitis—Sunitinib—pancreatic cancer	0.000531	0.00412	CcSEcCtD
Pyrazinamide—Urticaria—Fluorouracil—pancreatic cancer	0.000529	0.0041	CcSEcCtD
Pyrazinamide—Body temperature increased—Fluorouracil—pancreatic cancer	0.000526	0.00408	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.00052	0.00403	CcSEcCtD
Pyrazinamide—Hypersensitivity—Irinotecan—pancreatic cancer	0.000512	0.00397	CcSEcCtD
Pyrazinamide—Arthralgia—Docetaxel—pancreatic cancer	0.000501	0.00388	CcSEcCtD
Pyrazinamide—Myalgia—Docetaxel—pancreatic cancer	0.000501	0.00388	CcSEcCtD
Pyrazinamide—Nausea—Sunitinib—pancreatic cancer	0.000501	0.00388	CcSEcCtD
Pyrazinamide—Dysuria—Doxorubicin—pancreatic cancer	0.000493	0.00382	CcSEcCtD
Pyrazinamide—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00049	0.0038	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000481	0.00373	CcSEcCtD
Pyrazinamide—Pruritus—Gemcitabine—pancreatic cancer	0.000479	0.00371	CcSEcCtD
Pyrazinamide—Pruritus—Fluorouracil—pancreatic cancer	0.000471	0.00365	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00047	0.00365	CcSEcCtD
Pyrazinamide—Anorexia—Docetaxel—pancreatic cancer	0.000458	0.00355	CcSEcCtD
Pyrazinamide—Hepatitis—Epirubicin—pancreatic cancer	0.000456	0.00353	CcSEcCtD
Pyrazinamide—Vomiting—Irinotecan—pancreatic cancer	0.000442	0.00342	CcSEcCtD
Pyrazinamide—Rash—Irinotecan—pancreatic cancer	0.000438	0.0034	CcSEcCtD
Pyrazinamide—Dermatitis—Irinotecan—pancreatic cancer	0.000438	0.00339	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000438	0.00339	CcSEcCtD
Pyrazinamide—Vomiting—Gemcitabine—pancreatic cancer	0.00043	0.00334	CcSEcCtD
Pyrazinamide—Rash—Gemcitabine—pancreatic cancer	0.000427	0.00331	CcSEcCtD
Pyrazinamide—Dermatitis—Gemcitabine—pancreatic cancer	0.000426	0.00331	CcSEcCtD
Pyrazinamide—Vomiting—Fluorouracil—pancreatic cancer	0.000423	0.00328	CcSEcCtD
Pyrazinamide—Dyspepsia—Docetaxel—pancreatic cancer	0.000423	0.00328	CcSEcCtD
Pyrazinamide—Hepatitis—Doxorubicin—pancreatic cancer	0.000422	0.00327	CcSEcCtD
Pyrazinamide—Rash—Fluorouracil—pancreatic cancer	0.00042	0.00325	CcSEcCtD
Pyrazinamide—Dermatitis—Fluorouracil—pancreatic cancer	0.000419	0.00325	CcSEcCtD
Pyrazinamide—Decreased appetite—Docetaxel—pancreatic cancer	0.000418	0.00324	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000415	0.00321	CcSEcCtD
Pyrazinamide—Nausea—Irinotecan—pancreatic cancer	0.000413	0.0032	CcSEcCtD
Pyrazinamide—Nausea—Gemcitabine—pancreatic cancer	0.000402	0.00312	CcSEcCtD
Pyrazinamide—Feeling abnormal—Docetaxel—pancreatic cancer	0.000396	0.00307	CcSEcCtD
Pyrazinamide—Nausea—Fluorouracil—pancreatic cancer	0.000395	0.00306	CcSEcCtD
Pyrazinamide—Body temperature increased—Docetaxel—pancreatic cancer	0.00038	0.00294	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000368	0.00286	CcSEcCtD
Pyrazinamide—Malaise—Epirubicin—pancreatic cancer	0.000358	0.00278	CcSEcCtD
Pyrazinamide—Hypersensitivity—Docetaxel—pancreatic cancer	0.000354	0.00274	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000341	0.00264	CcSEcCtD
Pyrazinamide—Pruritus—Docetaxel—pancreatic cancer	0.00034	0.00263	CcSEcCtD
Pyrazinamide—Myalgia—Epirubicin—pancreatic cancer	0.000338	0.00262	CcSEcCtD
Pyrazinamide—Arthralgia—Epirubicin—pancreatic cancer	0.000338	0.00262	CcSEcCtD
Pyrazinamide—Discomfort—Epirubicin—pancreatic cancer	0.000334	0.00259	CcSEcCtD
Pyrazinamide—Malaise—Doxorubicin—pancreatic cancer	0.000331	0.00257	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000317	0.00246	CcSEcCtD
Pyrazinamide—Myalgia—Doxorubicin—pancreatic cancer	0.000313	0.00242	CcSEcCtD
Pyrazinamide—Arthralgia—Doxorubicin—pancreatic cancer	0.000313	0.00242	CcSEcCtD
Pyrazinamide—Discomfort—Doxorubicin—pancreatic cancer	0.000309	0.0024	CcSEcCtD
Pyrazinamide—Anorexia—Epirubicin—pancreatic cancer	0.000309	0.00239	CcSEcCtD
Pyrazinamide—Vomiting—Docetaxel—pancreatic cancer	0.000305	0.00237	CcSEcCtD
Pyrazinamide—Rash—Docetaxel—pancreatic cancer	0.000303	0.00235	CcSEcCtD
Pyrazinamide—Dermatitis—Docetaxel—pancreatic cancer	0.000303	0.00235	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000295	0.00229	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000294	0.00228	CcSEcCtD
Pyrazinamide—Anorexia—Doxorubicin—pancreatic cancer	0.000286	0.00222	CcSEcCtD
Pyrazinamide—Nausea—Docetaxel—pancreatic cancer	0.000285	0.00221	CcSEcCtD
Pyrazinamide—Dyspepsia—Epirubicin—pancreatic cancer	0.000285	0.00221	CcSEcCtD
Pyrazinamide—Decreased appetite—Epirubicin—pancreatic cancer	0.000282	0.00218	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.00028	0.00217	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000273	0.00212	CcSEcCtD
Pyrazinamide—Feeling abnormal—Epirubicin—pancreatic cancer	0.000267	0.00207	CcSEcCtD
Pyrazinamide—Dyspepsia—Doxorubicin—pancreatic cancer	0.000264	0.00205	CcSEcCtD
Pyrazinamide—Decreased appetite—Doxorubicin—pancreatic cancer	0.000261	0.00202	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000259	0.00201	CcSEcCtD
Pyrazinamide—Urticaria—Epirubicin—pancreatic cancer	0.000257	0.002	CcSEcCtD
Pyrazinamide—Body temperature increased—Epirubicin—pancreatic cancer	0.000256	0.00199	CcSEcCtD
Pyrazinamide—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000247	0.00191	CcSEcCtD
Pyrazinamide—Hypersensitivity—Epirubicin—pancreatic cancer	0.000239	0.00185	CcSEcCtD
Pyrazinamide—Urticaria—Doxorubicin—pancreatic cancer	0.000238	0.00185	CcSEcCtD
Pyrazinamide—Body temperature increased—Doxorubicin—pancreatic cancer	0.000237	0.00184	CcSEcCtD
Pyrazinamide—Pruritus—Epirubicin—pancreatic cancer	0.000229	0.00178	CcSEcCtD
Pyrazinamide—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000221	0.00171	CcSEcCtD
Pyrazinamide—Pruritus—Doxorubicin—pancreatic cancer	0.000212	0.00164	CcSEcCtD
Pyrazinamide—Vomiting—Epirubicin—pancreatic cancer	0.000206	0.0016	CcSEcCtD
Pyrazinamide—Rash—Epirubicin—pancreatic cancer	0.000204	0.00158	CcSEcCtD
Pyrazinamide—Dermatitis—Epirubicin—pancreatic cancer	0.000204	0.00158	CcSEcCtD
Pyrazinamide—Nausea—Epirubicin—pancreatic cancer	0.000192	0.00149	CcSEcCtD
Pyrazinamide—Vomiting—Doxorubicin—pancreatic cancer	0.000191	0.00148	CcSEcCtD
Pyrazinamide—Rash—Doxorubicin—pancreatic cancer	0.000189	0.00147	CcSEcCtD
Pyrazinamide—Dermatitis—Doxorubicin—pancreatic cancer	0.000189	0.00146	CcSEcCtD
Pyrazinamide—Nausea—Doxorubicin—pancreatic cancer	0.000178	0.00138	CcSEcCtD
